<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; ingredients</title>
	<atom:link href="http://www.tapanray.in/tag/ingredients/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Impact of The Cost of Pharma Marketing Failure On Patients</title>
		<link>http://www.tapanray.in/impact-of-the-cost-of-pharma-marketing-failure-on-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=impact-of-the-cost-of-pharma-marketing-failure-on-patients</link>
		<comments>http://www.tapanray.in/impact-of-the-cost-of-pharma-marketing-failure-on-patients/#comments</comments>
		<pubDate>Mon, 12 Sep 2022 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[controllable]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[send]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[uncontrollable]]></category>
		<category><![CDATA[variables]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10707</guid>
		<description><![CDATA[‘About half of all products launched over the past 15 years have underperformed pre-launch consensus forecasts by more than 20%.’ It’s one of the findings of a recent study by L.E.K. Consulting, going back to 2004. This number is besides the cost of &#8230; <a href="http://www.tapanray.in/impact-of-the-cost-of-pharma-marketing-failure-on-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/impact-of-the-cost-of-pharma-marketing-failure-on-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In Pharma’s Moment of Truth &#8220;What You Do is Who You Are&#8221;</title>
		<link>http://www.tapanray.in/in-pharmas-moment-of-truth-what-you-do-is-who-you-are/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-pharmas-moment-of-truth-what-you-do-is-who-you-are</link>
		<comments>http://www.tapanray.in/in-pharmas-moment-of-truth-what-you-do-is-who-you-are/#comments</comments>
		<pubDate>Mon, 13 Jul 2020 00:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA["What You Do is Who You Are"]]></category>
		<category><![CDATA[battle]]></category>
		<category><![CDATA[contemporary]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[cross-roads]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[initiatives]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resources]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[truth]]></category>
		<category><![CDATA[war]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10169</guid>
		<description><![CDATA[It’s a time when pharma industry will be tested, both by its external and internal customers – more than ever before. Looking back, in search of footprints on the sand is no answer either, as there isn’t any. But, a &#8230; <a href="http://www.tapanray.in/in-pharmas-moment-of-truth-what-you-do-is-who-you-are/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-pharmas-moment-of-truth-what-you-do-is-who-you-are/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Coronavirus Outbreak: Drug Shortage, Treatment And Unease – A Review</title>
		<link>http://www.tapanray.in/coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review</link>
		<comments>http://www.tapanray.in/coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review/#comments</comments>
		<pubDate>Mon, 09 Mar 2020 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[26 drugs]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[bullet]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[disruption]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Drug Shortage]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[hand]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[import ban]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[masks]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[N95]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[Outbreak]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[sanitizer]]></category>
		<category><![CDATA[serum Institute]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transmitted]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[Unease]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9903</guid>
		<description><![CDATA[The Coronavirus outbreak has reached a &#8220;decisive point&#8221; and has &#8220;pandemic potential&#8221;, said the Director General of the World Health Organization (W.H.O), reportedly, on February 27, 2020, urging governments to act swiftly and aggressively to contain the virus. He further added, &#8220;We are &#8230; <a href="http://www.tapanray.in/coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>China Coronavirus And API Sourcing &#8211; A Threat… Or An Opportunity For India?</title>
		<link>http://www.tapanray.in/china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india</link>
		<comments>http://www.tapanray.in/china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india/#comments</comments>
		<pubDate>Mon, 03 Feb 2020 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2019-nCoV]]></category>
		<category><![CDATA[Active]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[green]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Kerala]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[shoots]]></category>
		<category><![CDATA[sourcing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9858</guid>
		<description><![CDATA[‘2015 – Year of Active Pharmaceutical Ingredients’ (API), announced the Government of India by a Press Release on February 25, 2015. This came after ascertaining that over-dependence on imports of bulk drugs or API, especially from China, is detrimental to India’s health &#8230; <a href="http://www.tapanray.in/china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s China Dependence On API: A Time To Think ‘Outside The Box’</title>
		<link>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-china-dependence-on-api-a-time-to-think-outside-the-box</link>
		<comments>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/#comments</comments>
		<pubDate>Mon, 21 Sep 2015 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Active]]></category>
		<category><![CDATA[Advisor]]></category>
		<category><![CDATA[Ananth Kumar]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ASSOCHAM]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[dependence]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Katoch]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[out of box]]></category>
		<category><![CDATA[outside]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[year of API]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7086</guid>
		<description><![CDATA[The Department of Pharmaceuticals (DoP) has declared the Year 2015 as the Year of ‘Active Pharmaceutical Ingredient (API)’. Following it up on February 25, 2015, the Union Minister of Chemicals &#38; Fertilizers Ananth Kumar assured the Pharmaceutical Industry that appropriate &#8230; <a href="http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Fraud or Negligence in Drug Quality Standards Not a Fraud on Patients?</title>
		<link>http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients</link>
		<comments>http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/#comments</comments>
		<pubDate>Mon, 03 Jun 2013 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Americans]]></category>
		<category><![CDATA[anywhere]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Boehringer]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[breach]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[charitable]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Claris]]></category>
		<category><![CDATA[contamination]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dewas]]></category>
		<category><![CDATA[Dr. Reddy's]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[everywhere]]></category>
		<category><![CDATA[facilities]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Heparin]]></category>
		<category><![CDATA[Hospira]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[IMA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Ingelheim]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[Jaslok]]></category>
		<category><![CDATA[Jubilant]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Medical Association]]></category>
		<category><![CDATA[Mumbai]]></category>
		<category><![CDATA[OSCS]]></category>
		<category><![CDATA[paonta]]></category>
		<category><![CDATA[pew]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[plants]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sahib]]></category>
		<category><![CDATA[Schering-Plough]]></category>
		<category><![CDATA[SCS]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Show]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tolerance]]></category>
		<category><![CDATA[tragedy]]></category>
		<category><![CDATA[trusts]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Wyeth]]></category>
		<category><![CDATA[zero]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2607</guid>
		<description><![CDATA[As we know, a substance is called a drug when it has scientifically proven and well documented efficacy and safety profile to reduce both mortality and morbidity of patients. Any fraud or negligence in the drug quality standards, for whatever &#8230; <a href="http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The domestic API players are fast losing their dominance in the Indian API market</title>
		<link>http://www.tapanray.in/the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market</link>
		<comments>http://www.tapanray.in/the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market/#comments</comments>
		<pubDate>Mon, 24 Oct 2011 00:30:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Active]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[dominance]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[fast]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[losing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[their]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=184</guid>
		<description><![CDATA[There are two broad categories of markets for the Active Pharmaceutical Ingredients (API) across the world namely, highly regulated and semi regulated markets. Countries like, USA, Europe and Japan will fall under highly regulated category with high entry barriers for &#8230; <a href="http://www.tapanray.in/the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
